New Oral Solution Form of Epaned Gains Approval

The new oral solution is indicated to threat hypertension in adults and children over 1 month old
The new oral solution is indicated to threat hypertension in adults and children over 1 month old

The Food and Drug Administration (FDA) has approved Epaned (enalapril maleate; Silvergate Pharmaceuticals) Oral Solution for the treatment of hypertension in adults and children >1 month, to lower blood pressure. It is also indicated to treat symptomatic heart failure and asymptomatic left ventricular dysfunction.

Epaned is already available as a Kit containing 150mg/150mL powder for oral solution after reconstitution. The new Oral Solution has a 22 month expiry when stored refrigerated and a 60 day in-use period after dispensing, when stored at room temperature.

Related Articles

Enalapril, after hydrolysis to enalaprilat, inhibits angiotensin-converting enzyme (ACE). The beneficial effects of enalapril in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. Inhibition of ACE results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and decreased aldosterone secretion.

Epaned Oral Solution will be available as a 1mg/mL strength with a mixed berry flavor in 150mL bottles. 

For more information call (855) 379-0383 or visit Epaned.com.

Loading links....